PACE 4/13 * RCVD AT 8/25/2004 3:53:18 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/4 * DNIS:8729306 * CSID:502 587 6391 * DURATION (mm-ss):02-44

control of the same regulatory element; and

CLAIMS

Application No. 09/820,531
Reply to Office Action of August 23, 2004

What is claimed is:

1-33. (canceled)

(previously presented) A method for screening for genes whose expression is altered

by disease, age, or exogenous agent, comprising: screening a sample microarray comprising genes from a library, cells or animal

exposed to the disease, age or exogenous agent, wherein expression of all of the genes is under

cells or animal not exposed to the disease, age or exogenous agent. comparing the expression of the genes to expression of control genes from a library,

(currently amended) The method of claim 34 A method for screening for genes whose

screening a sample microarray comprising genes from a library, cells or animal

expression is altered by disease, age, or exogenous agent, comprising

exposed to the disease, age or exogenous agent, wherein expression of all of the genes is under

control of the same regulatory element; and comparing the expression of the genes to expression of control genes from a library

cells or animal not exposed to the disease, age or exogenous agent

wherein the microarray further comprises control genes that are not under the control

of the same regulatory element

STITES & HARBISON 3:25bW 4002 .25. 8uA

PAGE 5/13 * RCVD AT 8/25/2004 3:53:18 PM (Eastern Daylight Time) * SVR:USPTO-EFXRF-1/4 * DNIS:8729306 * CSID:502 587 6391 * DURATION (mm-ss):02-44

Application No. 09/820,531
Reply to Office Action of August 23, 2004

36. (currently amended) The method of eleim 34 A method for screening for genes whose

expression is aftered by disease, age, or exogenous agent, comprising;

exposed to the disease, age or exogenous agent, wherein expression of all of the genes is under control of the same regulatory element; and

comparing the expression of the genes to expression of control genes from a library

cells or animal not exposed to the disease, age or exogenous agent

wherein the regulatory element is selected from the group of regulatory elements consisting of osmotic response element, retinoic acid response element, conserved proximal sequence element, vitamin D response element, sterol response element, TNF-alpha response element, serum response element, cAMP response element, antioxidant response element, glucotocorticoid modulatory element, gonadotropin-releasing hormone-response element, pheromone response element, insulin response element, interferon consensus response element, estrogen response element, hypoxia response element, E2F transcription factor, xenobiotic response element, endoplasmic reticulum stress response element, iron-response element, androgen response element, stress response element, RAS-responsive element binding protein 1, and transforming growth factor, beta-1 response element.

37. (canceled)

38. (original) The method of claim 34 wherein the disease is selected from the group consisting of neurological disorders, cardiovascular disorders, bone and muscle disorders, blood or

Aug.25. 2004 3:52PM STITES & HARBISON

PACE 6/13 * RCVD AT 8/25/2004 3:53:18 PM [Eastern Daylight Time] * SVR: USPTO-EFXRF-1/4 * DNIS:8729306 * CSID:502 587 6391 * DURATION (mm-ss):02-44

heptatomas

Application No. 09/820,531
Reply to Office Action of August 23, 2004

circulation related disorders, and cancer.

(original) The method of claim 38 wherein the diseases are selected from the group

consisting of breast cancer, prostatic hypertrophy, prostatic cancer, colon cancer, chronic (original) The method of claim 38 wherein the cancers are selected from the group

lymphocytic leukemia, acute lymphocytic leukemia, brain tumors, pancreatic cancer, and

disorders.

41, (canceled)

(previously presented) The method of claim 34 wherein the exogenous agent is a drug

43

or toxin.

₽. (previously presented) The method of claim 34 wherein the library is derived from

cells or tissues treated with one or more compounds in vitro.

cells obtained from an individual of a particular age, having a particular disease or disorder, or <u>4</u> (previously presented) The method of claim 34 wherein the library is derived from

> SILLES & HARBISON 3:25PM 2004 .62.8uA

hypertrophy, atherosclerosis, myocardial infarction, osteoarthritis, osteoporosis, and autoimmune consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, myocardial PAGE 7/13 * RCVD AT 8/25/2004 3:53:18 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/4 * DNIS:8729306 * CSID:502 587 6391 * DURATION (mm-ss):02-44

Application No. 09/820,531
Reply to Office Action of August 23, 2004

cancerous tissues.

45. (previously presented) The method of claim 34 wherein the exogenous agent is

derived from the neurological system, the cardiovascular system, the musculoskeletal system, or

46. (previously presented) The method of claim 43 wherein the compound is selected from the group consisting of proteins or peptides, sugars or polysaccharides, nucleic acid molecules,

molecules, and synthetic molecules.

selected from the group consisting of proteins or peptides, sugars or polysaccharides, nucleic acid

and synthetic molecules.

47. (new) The method of claim 35 wherein the disease is selected from the group

consisting of neurological disorders, cardiovascular disorders, bone and muscle disorders, blood or

circulation related disorders, and cancer.

- 48. (new) The method of claim 47 wherein the diseases are selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, myocardial hypertrophy, atherosclerosis, myocardial infarction, osteoarthritis, osteoporosis, and autoimmune disorders.
- 49. (new) The method of claim 47 wherein the cancers are selected from the group consisting of breast cancer, prostatic hypertrophy, prostatic cancer, colon cancer, chronic

0

PAGE 8/13 * RCVD AT 8/25/2004 3:53:18 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/4 * DNIS:8729306 * CSID:502 587 6391 * DURATION (mm-ss):02-44

Application No. 09/820,531
Reply to Office Action of August 23, 2004

heptatomas.

lymphocytic leukemia, acute lymphocytic leukemia, brain tumors, pancreatic cancer, and

50. (new) The method of claim 35 wherein the exogenous agent is a drug or toxin.

(new) The method of claim 35 wherein the library is derived from cells or tissues

-treated with one or more compounds in vitro.

53. (new) The method of claim 35 wherein the exogenous agent is selected from the

an individual of a particular age, having a particular disease or disorder, or derived from the neurological system, the cardiovascular system, the musculoskeletal system, or cancerous tissues.

(new) The method of claim 35 wherein the library is derived from cells obtained from

group consisting of proteins or peptides, sugars or polysaccharides, nucleic acid molecules, and

synthetic molecules.

54. (new) The method of claim 35 wherein the compound is selected from the group consisting of proteins or peptides, sugars or polysaccharides, nucleic acid molecules, and synthetic

molecules.

-3

Aug.25. 2004 3:53PM STITES & HARBISON